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Background: Mortality in female patients with ST-segment elevation myocardial infarction (STEMI) undergoing
primary angioplasty (pPCI) is higher than in men. We examined gender differences in the prevalence and
prognostic performance of renal dysfunction at admission in this setting.
Methods: A multicenter retrospective sub-analysis of the Belgian STEMI-registry identified 1,638 patients (20.6%
women, 79.4% men) treated with pPCI in 8 tertiary care hospitals (January 2007-February 2011). The estimated
glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation. Main outcome measure was in-hospital
mortality.
Results: More women than men suffered from renal dysfunction at admission (42.3% vs. 25.3%, p < 0.001). Mortality
in women was doubled as compared to men (9.5 vs. 4.7%, OR (95% CI) = 2.12 (1.36-3.32), p<0.001). In-hospital
mortality for men and women with vs. without renal dysfunction was much higher (10.7 and 15.3 vs. 2.3 and 2.4%,
p < 0.001). In a multivariable regression analysis, adjusting for age, gender, peripheral artery disease (PAD), coronary
artery disease (CAD), hypertension, diabetes and low body weight (<67 kg), female gender was associated with
renal dysfunction at admission (OR (95% CI) 1.65 (1.20-2.25), p = 0.002). In a multivariable model including TIMI risk
score and renal dysfunction, renal dysfunction was an independent predictor of in-hospital mortality in both men
(OR (95% CI) = 2.39 (1.27-4.51), p = 0.007) and women (OR (95% CI) = 4.03 (1.26-12.92), p = 0.02), with a comparable
impact for men and women (p for interaction = 0.69).
Conclusions: Female gender was independently associated with renal dysfunction at admission in pPCI treated
patients. Renal dysfunction was equally associated with higher in-hospital mortality in both men and women.
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It has been demonstrated that women with STEMI under-
going primary PCI (pPCI) have higher odds for in-hospital
mortality than men. Some authors demonstrated that this
difference is likely explained by their older age and base-
line comorbidities (especially hypertension and diabetes)
[1-5], while other authors demonstrated a sustained mor-
tality difference even after adjustment for appropriate con-
founders [6-8]. Chronic kidney disease, even mild, is
associated with increased cardiovascular mortality [9].
More recently it was demonstrated that renal dysfunction
is independently associated with in-hospital mortality in
STEMI patients treated with pPCI [10-12].
Data on gender differences in prevalence of renal dys-
function at admission in pPCI treated STEMI patients
are scarce and have seldom been accounted for when
evaluating gender differences in outcome, furthermore
different definitions (serum creatinine levels vs. esti-
mated Glomerular Filtration Rate (eGFR) values) and
different methods of estimating creatinine clearance
have been applied [2,4,8,13].
The GFR cannot be measured easily in clinical prac-
tice, instead it is estimated (eGFR) from equations, using
variables such as serum creatinine level, age, body
weight, race and sex. The most recent equation, the
CKD-EPI equation (Chronic Kidney Disease Epidemi-
ology Collaboration), published in 2009, is more precise
and accurate than other equations such as the Cockroft-
Gault, the MDRD- (Modification of Diet in renal Dis-
ease) and the re-expressed MDRD equation, especially at
GFRs > 60 mL/min/1.73 m2 [14,15]. The CKD-EPI equa-
tion usually yields higher values for eGFR than the
MDRD study equation, probably because it was devel-
oped in a more diverse study population, including par-
ticipants with and without CKD. Therefore it is assumed
that the CKD-EPI equation leads to smaller average bias
in clinical populations with a wide range of GFRs, such
as the STEMI population [16]. In a recent analysis of the
PLATO trial, including 18,624 patients with an acute
coronary syndrome, the CKD-EPI formula exhibited the
highest prognostic value and produced a clinical relevant
cut-off of 60 mL/min/1.73 m2 [17].
The Thrombolysis In Myocardial Infarction (TIMI)
risk score for STEMI is a simple arithmetic score that
predicts short-term mortality based on age and clinical
data on admission [18]. This score was initially devel-
oped and validated in a randomized controlled trial of
patients treated with fibrinolysis but proved to be useful
in patients treated with primary PCI in an observational
registry (c statistic = 0.80 for patients treated with pri-
mary PCI in the NRMI III registry (N = 15,348)) [19].
Accordingly, we evaluated differences in prevalence of
renal dysfunction at admission, defined as an eGFR <
60 mL/min/1.73 m2, in men and women presenting withSTEMI and treated with pPCI, using the CKD-EPI equa-
tion for assessment of eGFR. We assessed the prognostic
impact of renal dysfunction at admission, on top of the
TIMI risk score, on in-hospital mortality in men and
women and finally we evaluated whether there was an
interaction between female gender and renal dysfunction
regarding in-hospital mortality.
As far as we are aware this is the first study that inves-
tigates gender differences in prevalence and prognostic
value of renal dysfunction, assessed by the CKD-EPI
equation, in a subgroup of currently PCI-treated STEMI
patients included in a national STEMI-registry.
Methods
Study population
The Belgian STEMI registry is a prospective observational
registry of Belgian STEMI patients from 72 Belgian hospi-
tals that contains demographics, clinical characteristics
at admission, practice patterns and in-hospital outcomes.
The registry is an initiative from the Belgian Working
Group on Acute Cardiology (BIWAC) and is supported by
the Belgian Government of Social Affairs and Public
Health and the Belgian College of Cardiologists. Belgium
constitutes a catchment area of 11.000.000 persons. All
Belgian cardiologists working in hospitals with acute care
facilities were required to prospectively collect data on all
admitted STEMI patients (symptoms suspicious of acute
coronary syndrome, combined with ST-segment elevation
or new left bundle branch block on ECG) starting from
January 2007.
During the period January 2007 to February 2011, a
total of 9,535 (24.7% women) patients from 72 hospitals
(25 with PCI facilities and 47 without PCI facilities) were
prospectively included in the STEMI registry. We retro-
spectively collected admission values of creatinine of pa-
tients (N = 1,751; 20.7% women) admitted in the eight
tertiary care centers that participated in this sub-analysis.
Of these 1,638 (20.6% women) were treated with primary
PCI <24 hours after hospital admission and included in
the analysis (Figure 1).
A yearly audit, conducted by an external commission,
of 10% of all patient files was performed to verify the
validity of the data; the evaluation of these files demon-
strated a 96% concordance rate between source docu-
ments and case report forms. Data were electronically
collected via a protected eCRF. The database is managed
by an independent electronic data-capture provider
(Lambda Plus, SA, Gembloux, Belgium).
TIMI risk score
The TIMI risk score was automatically calculated from 8
differentially weighted clinical indicators ascertained
upon admission. The TIMI score ranges from 0 to 14
and is calculated as follows: age (2 points: 65–74, 3
Figure 1 Study population, undergoing primary PCI in 8 (out of 25) selected centers.
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hypertension (1 point); admission systolic blood pres-
sure (BP) <100 mmHg (3 points); admission heart rate
(HR) >100 beats/min (bpm) (2 points); admission Killip
class > I (2 points); admission weight <67 kg (1 point);
anterior infarction or left bundle branch block LBBB
(1 point); and time to reperfusion therapy > 4 hours
(1 point) [18].
GFR measurement
We defined renal dysfunction as an eGFR < 60 mL/min/
1.73 m2, corresponding to National Kidney Foundation
Kidney Disease Outcomes Quality Initiative (NKF KDOQI)
stages 3 to 5 of chronic kidney disease. The eGFR was cal-
culated using the CKD-EPI equation based on the admis-
sion value of serum creatinine [14] as follows:
eGFR = 141 x min (Scr/k, 1)a x max (Scr/k, 1)-1.209 x
0.993age [x 1.018 if female] [x 1.159 if black], where Scr is
serum creatinine, k is 0.7 for females and 0.9 for males, a is
−0.329 for females and −0.411 for males. The eGFR could
not be calculated in 11.9% of the cases, due to missing
values. We found no differences in proportions of women
or baseline characteristics between patients with and with-
out missing values, except for the incidence of Cardio Pul-
monary Resuscitation (CPR) (19.5% vs. 10.1%, p < 0.001)
and in-hospital mortality (9.7 vs. 5.1%, p = 0.009).
Outcome data
The primary endpoint existed of in-hospital mortality.
Statistical analysis
We compared the baseline characteristics, including
renal dysfunction at admission, and in-hospital out-
comes of women with those of men. Distributions of
categorical variables were compared by using the Fisher
exact test. Continuous variables were evaluated for nor-
mality. The Student's t test was used for continuousvariables with a normal distribution (presented as the
mean ± SD), and the Mann Whitney-U test was used for
continuous variables (presented as the median and inter-
quartile range (IQR)) without a normal distribution.
Multivariable logistic-regression analysis was used to de-
termine the independent predictors of renal dysfunction
at admission including following covariates in the model:
gender, age, bodyweight <67 kg, history of coronary ar-
tery disease (CAD), history of peripheral artery disease
(PAD), hypertension and diabetes. Separate logistic re-
gression analyses were performed regarding in-hospital
mortality for each gender, including TIMI risk score as a
continuous and renal dysfunction as a dichotomous vari-
able in the model. Multivariable logistic regression ana-
lysis was also used to assess a possible interaction
between gender and renal dysfunction regarding in-
hospital mortality adding renal dysfunction and gender
as dichotomous variables and the product of gender and
eGFR < 60 mL/min/1.73 m2 as an interaction term to
the previous model. All multivariable analyses were
based on complete patient records.
Adjusted Odds Ratios (OR) with 95% confidence inter-
vals (CI) are reported. Statistical significance was defined
as p < 0.05 or 95% confidence intervals (CI) for OR that
did not include 1.0. All statistical analyses were
performed using the SPSS 19 statistical software.
Ethics approval
This study was approved by the central ethical commit-
tee of the Ghent University Hospital (2011/455). In-
formed consent was obtained from all patients or their
legal representatives.
Results
Baseline characteristics
During the period between January 2007 and February
2011, 1,638 patients were treated with primary PCI in
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male and 1,300 (79,4%) were male. Baseline patient char-
acteristics are shown in Table 1. As compared to men,
women were on average 7 years older and more had dia-
betes, hypertension, and a body weight <67 kg. Further-
more, less women had previous CAD as compared to
men. The history of PAD between women and men was
not different. Women had longer total ischemic times.
The need for CPR was not different between women
and men. The Killip class and TIMI risk score at admis-
sion were higher in women vs. men. Door to balloon
times (DTB) were comparable among women and men.
Gender and renal dysfunction
Median creatinine values were higher in men vs. women
(median creatinine in men 1.0 [0.84-1.17] vs. 0.9 [0.75-
1.10] in women, p < 0.001). Renal dysfunction, defined as
an eGFR below 60 mL/min per 1.73 m2 or a Chronic Kid-
ney Disease (CKD) stage 3, 4 or 5 was more frequently ob-
served in female patients (42.3% vs. 25.3%, p < 0.001)
(Figure 2). In a multivariable regression analysis, including
age (/year), hypertension, diabetes, CAD or PAD and a
body weight below 67 kg, female gender remained inde-
pendently associated with renal dysfunction (OR 1.65,
95%CI 1.20 to 2.25, p = 0.002). Age and PAD were two
other powerful determinants of renal impairment (Age:
OR 1.07, 95%CI 1.05 to 1.08, p < 0.001, PAD: OR 1.89,
95% CI 1.26 to 2.84, p = 0.002). Coronary artery disease
was borderline significant as a determinant of renal dys-
function (OR 1.35, 95% CI 1.00 to 1.82, p = 0.05) (Table 2).Table 1 Baseline patient characteristics (N = 1,638)
Characteristic Women (N = 338, 20.6%
Age, mean (SD), years 68.8 (12.7)
Diabetes 21.3
Hypertension 54.7
Weight < 67 kg 42.3
Previous CAD (a) 16.9
Previous PAD (b) 8.6
Ischemic time > 4 h (c) 47
Door to balloon > 120 min. 14.2
CPR (d) 11.2
HR (e) > 100 bpm (f) 17.2
BP (g) < 100 mmHg 23.7
Anterior AMI (h) 49.4
Killip > I 26.6
TIMI score, median [IQR] 5 [3.0 – 7.3]
Creatinine (mg/dl) median [IQR] 0.90 [0.75-1.10]
eGFR (i) <60 mL/min/1.73 m2 42.3
(a) coronary artery disease, (b) peripheral artery disease, (c) ischemic time = symptom
minute, (g) systolic blood pressure, (h) acute myocardial infarction, (i) estimated glom
Data are presented as percentage of patients unless otherwise specified.Gender, baseline renal dysfunction and in-hospital
mortality
The in-hospital mortality rate for the entire cohort of pPCI
treated patients was 5.7%. Mortality in women was dou-
bled as compared to men (9.5 vs. 4.7%), OR = 2.12 (95% CI
1.36 to 3.32, p < 0.001). Mortality in patients with renal
dysfunction at the time of hospital admission was much
higher compared to those without (12.0% vs. 2.3%, p <
0.001). In-hospital mortality was comparable in men and
women without renal impairment: 2.3% vs. 2.4%, while
there was a non-significant trend for higher mortality in
women with renal dysfunction compared to men with
renal dysfunction (15.3% vs. 10.7%, p = 0.18) (Figure 3).
TIMI risk score and additive prognostic performance of
baseline renal dysfunction in men and women
In a multivariable regression analysis including gender,
TIMI risk score and renal dysfunction, both TIMI risk
score (OR = 1.47, 95% CI 1.35-1.60) and renal dysfunction
(OR 2.71, 95% CI 1.56-4.69) were strong predictors of in-
hospital mortality; there was a trend towards higher mor-
tality in women (OR 1.45, 95% CI 0.8-2.63).
Adding renal dysfunction to the TIMI risk score in
men and women separately in a multivariable logistic re-
gression model demonstrated that renal dysfunction was
an independent predictor of in-hospital mortality in both
men (OR (95% CI) = 2.39 (1.27-4.51), p = 0.007) and
women (OR (95% CI) = 4.03 (1.26-12.92), p = 0.02), the
interaction test demonstrated that this impact was com-
parable for men and women (p = 0.69).) Men (N = 1300, 79.4%) P-value
61.6 (12.0) <0.001
13.8 <0.001
41.4 <0.001
9.8 <0.001
22.4 0.03
8.4 0.91
35 <0.001
11.8 0.59
11.2 1.00
11.5 <0.001
15.3 <0.001
45.1 0.16
14.3 <0.001
3 [2.0 – 5.0] <0.001
1.00 [0.84-1.17] <0.001
25.3 <0.001
to balloon time, (d) cardiopulmonary resuscitation, (e) heart rate, (f) beats per
erular filtration rate.
Figure 2 Chronic Kidney Disease (CKD) stage at admission according to gender. CKD 1: Chronic Kidney disease stage 1: eGFR≥ 90 mL/
min/1.73 m2. CKD 2: Chronic Kidney disease stage 2: eGFR≥ 60 - < 90 mL/min/1.73 m2. CKD 3: Chronic Kidney disease stage 3: eGFR≥ 30 -
< 60 mL/min/1.73 m2. CKD 4: Chronic Kidney disease stage 4: eGFR≥ 15 - < 30 mL/min/1.73 m2. CKD 5: Chronic Kidney disease stage 5: eGFR <
15 mL/min/1.73 m2. Blue bars = women. Red bars =men.
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In a sub-analysis of the Belgian STEMI registry, includ-
ing 20,3% of Belgian STEMI patients undergoing pPCI
for STEMI, we found that renal dysfunction at the time
of hospital admission (eGFR < 60 mL/min per 1.73 m2
or CKD class 3 or higher), assessed by the CKD-EPI for-
mula, was a common finding and that more women
(42.3%) than men (25.3%) suffered from this condition.
As expected, a CKD class 3 or higher on admission was
associated with in-hospital mortality, and this independ-
ently of the TIMI risk score. Although there was a trend
towards higher mortality for women with renal dysfunc-
tion compared to men with this condition, we could not
demonstrate a gender difference in the impact of renal
dysfunction on in-hospital mortality.
Despite the fact that male STEMI patients had a
higher serum creatinine concentration at admission, the
prevalence of renal dysfunction defined by an eGFR
<60 mL/min per 1.73 m2 and assessed with the CKD-
EPI formula was almost doubled in women as comparedTable 2 Determinants of admission renal dysfunction and
Odds Ratios after multivariable adjustment
Variable OR 95%CI p-value
Female gender 1.65 1.20-2.25 0.002
Age (/year) 1.07 1.05-1.08 <0.001
Weight < 67 kg 0.87 0.61-1.23 0.87
CAD (a) 1.35 1.00-1.82 0.05
PAD (b) 1.89 1.26-2.84 0.002
AHT (c) 1.10 0.84-1.43 0.49
DM (dcp 0.97 0.69-1.36 0.87
(a) coronary artery disease, (b) peripheral artery disease, (c) arterial hypertension,
(d) diabetes.to men, even after correction for observed differences in
age and risk profile between men and women. The
higher serum creatinine concentrations in men can eas-
ily be explained by the larger muscle mass, resulting in
greater creatinine generation, and a higher serum cre-
atinine concentration for a given GFR. This illustrates
that serum creatinine values should not be used to
evaluate gender differences in the impact of renal func-
tion on outcome. It is not completely clear why the inci-
dence of renal dysfunction is higher in women, we
cannot exclude that there are unknown confounders that
may explain this difference.
Many authors have demonstrated that women with
STEMI have a higher risk of in-hospital mortality and
some, but not all, could explain this higher mortality
based on age and the presence of more comorbidities, es-
pecially hypertension and diabetes [1-5]. Lawesson et al.
recently demonstrated in a small single center study, in-
cluding 274 STEMI patients undergoing pPCI, that female
gender was a strong and independent predictor of renal
dysfunction and that renal dysfunction had a possibly
higher impact on 1-year mortality in women (p for inter-
action = 0.08) [13]. We confirmed that renal dysfunction
was more prevalent in pPCI treated women but we did
not find a gender-impact on in-hospital mortality. Given
the fact that the prevalence of renal dysfunction was inde-
pendently related to female gender and that there was no
difference in mortality between women and men with pre-
served renal function we speculate that renal dysfunction
could be an important reason why women with STEMI
die more than men.
The presented data do not reveal why renal dysfunc-
tion was associated with worse outcome. There are nu-
merous data that demonstrate that chronic kidney
Figure 3 In-hospital mortality according to gender and renal function. eGFR = estimated glomerular filtration rate. Blue bars = women.
Red bars = men.
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Renal dysfunction may serve as a surrogate marker for
general health and for unknown risk factors that may ex-
plain the worse outcome. Also renal dysfunction may be
associated with complications, of which development of
(contrast induced) acute kidney injury (AKI) and bleed-
ing are the most likely to occur [20]. By implementing
routine calculation of eGFR, based on the CKD-EPI for-
mula, high risk patients can be identified, and strategies
for prevention of contrast induced AKI (bicarbonate ad-
ministration, optimization of hemodynamic status and
discontinuation of nephrotoxic drugs) [21] and other
complications (e.g. bleeding) can be initiated. More over,
evidence based therapies such as β-blockers, ACE-
inhibitors and statins should not be withheld in this sub-
group [22].
Today it is not clear whether the prognostic perform-
ance of the currently most used simple and bedside risk
scores could improve by adding eGFR to the model. Kid-
ney function, represented by various cut-offs for serum
creatinine but not by eGFR, is already incorporated in the
GRACE risk score [23]. Kidney function is not incorpo-
rated at all in the TIMI risk score for STEMI and this
might be one of the reasons why the GRACE risk score
performed better in STEMI patients in a recent meta-
analysis of 15 derivation studies and 17 validation studies
[24]. Given our finding that serum creatinine underesti-
mates renal dysfunction, especially in women, future risk
stratification should preferably use the eGFR based kidney
function estimates such as the CKD-EPI equation.
Strenghts and limitations
This study is unique as it represents the first dataset that
links gender, renal dysfunction, assessed by the CKD-EPI
equation, and outcomes in a subgroup of PCI-treatedSTEMI patients included in the Belgian STEMI registry.
As 71.2% of this Belgian STEMI cohort presented with
an eGFR > 60 mL/min/1.73 m2, the use of the CKD-EPI
equation was appropriate.
The study has some limitations. First, we only studied
patients who underwent pPCI in a subgroup of 8 tertiary
care centers that participated in the Belgian STEMI
registry; since it has been demonstrated that patients
with renal failure have less access to invasive therapy, a
selection bias is not excluded [25]. Second, it is uncer-
tain whether renal dysfunction at the time of hospital
admission represents a steady state condition of chronic
kidney disease or whether there was also a component
of AKI. Third, we only collected data on in-hospital
mortality rates; hence, it remains unclear whether our
results can be extrapolated to long-term outcomes. Fi-
nally, it is not clear how missing values could have
influenced our results, however we found no differences
in proportions of women and baseline characteristics,
except for a higher incidence of CPR in the group with
missing values. This and the higher in-hospital mortality
in this group suggest that these patients were more se-
verely ill and probably also had renal dysfunction at the
time of hospital admission, which would have reinforced
our findings.
Conclusions
Renal dysfunction, defined as an eGFR < 60 mL/kg per
1.73 m2 was common in a subgroup of patients under-
going primary PCI for STEMI and female gender was in-
dependently associated with this condition. Renal
dysfunction, independent of the TIMI risk score, was as-
sociated with higher in-hospital mortality rates in both
men and women. There was no gender difference in the
prognostic impact of renal dysfunction regarding in-
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tinely be assessed at baseline in these patients and these
and not serum creatinine values should be accounted for
when evaluating gender differences in outcome after
STEMI. Whether eGFR, assessed by the CKD-EPI equa-
tion, could improve the prognostic performance of cur-
rently used bedside risk stratification models remains to
be elucidated.
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